Targets › ATP5A1
3 programs from 3 companies in 3 trials: 3 Phase 2; Infectious disease; next expected readout May 2027.
Subunit alpha, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel. (UniProt, P25705)
Open in Phaseline: the race on ATP5A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Boston University | Bedaquiline ATP synthase inhibitor | ATP5A1 | Phase 2 | Tuberculosis, Multidrug-Resistant | May 2027 |
| Huashan Hospital | 3-month BDCZ regimen Combination of bedaquiline (ATP synthase inhibitor), delamanid (mycolic acid inhibitor), c | ATP5A1 | Phase 2 | Tuberculosis | Nov 2027 |
| Barwon Health | Telacebec Mycobacterial ATP synthase inhibitor | ATP5A1 | Phase 2 | Buruli Ulcer | Dec 2027 |
Tuberculosis (1) Tuberculosis, Multidrug-Resistant (1) Buruli Ulcer (1)
small molecule (3)
Huashan Hospital (1) Boston University (1) Barwon Health (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.